January 30, 2014
1 min read

Clearside announces patent allowance for microneedle drug delivery

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Clearside Biomedical announced that the U.S. Patent and Trademark Office granted U.S. Patent Application No. 13/453,407 as U.S. Patent No. 8,636,713 in the patent titled “Methods and devices for drug delivery to ocular tissue using microneedle.” This is Clearside’s third patent allowance in the U.S. related to the microneedle drug delivery methods and devices.

The patent, exclusively licensed to Clearside through May 2,  2027, deals with a method of administering an anti-inflammatory drug to a patient’s eye by inserting a hollow microneedle and infusing the drug into the suprachoroidal space.

Clearside Biomedical, headquartered in Alpharetta, Ga., is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapies to treat sight-threatening diseases.